STOCK TITAN
  1. Home
  2. News
  3. EXEL

Exelixis Inc - EXEL STOCK NEWS

Welcome to our dedicated news page for Exelixis (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exelixis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exelixis's position in the market.

News
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) will webcast the Exelixis 2023 R&D Day: Science & Strategy event on December 12, 2023, featuring speakers reviewing the company’s research and development pipeline, clinical updates, and efforts to serve more cancer patients and generate sustainable value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
-
News
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) has initiated the STELLAR-305 phase 2/3 pivotal trial to evaluate zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The trial will assess the potential of inhibition of VEGF, MET, and AXL, which are elevated in these tumors. This global, multicenter, randomized, double-blind study aims to provide a chemo-free treatment option for patients with incurable SCCHN. The primary endpoints are progression-free survival (PFS) and overall survival, with secondary endpoints including objective response rate and duration of response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
clinical trial
-
News
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
Rhea-AI Summary
Exelixis, Inc. (EXEL) and Arcus Biosciences (RCUS) have announced a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation TKI, in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors. Patient enrollment for STELLAR-009 is expected to begin before the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
clinical trial
News
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
Rhea-AI Summary
Exelixis, Inc. (EXEL) and Arcus Biosciences (RCUS) have announced a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis' next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). The trial is expected to begin enrolling patients before the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
clinical trial
-
News
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
Rhea-AI Summary
Exelixis, Inc. (EXEL) to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference. Webcast available on www.exelixis.com. Replay accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
conferences
-
News
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) announced positive initial results from the expansion cohort of STELLAR-001 evaluating zanzalintinib in previously treated clear cell renal cell carcinoma patients, with a 38% objective response rate and 88% disease control rate. Promising anti-tumor activity was observed in patients who had progressed on prior VEGFR-tyrosine kinase inhibitors, including cabozantinib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
clinical trial
News
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Exelixis, Inc. reported total revenues of $471.9 million for Q3 2023, with net product revenues of $426.5 million. The increase in net product revenues was driven by an increase in sales volume and average net selling price. Research and development expenses increased to $332.6 million, while selling, general, and administrative expenses increased to $138.1 million. GAAP net income for the quarter was $1.0 million, while non-GAAP net income was $32.1 million. Exelixis provided updated financial guidance for fiscal year 2023, with total revenues projected to be $1.825 billion - $1.850 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
earnings
-
News
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
Rhea-AI Summary
Exelixis announces positive results from phase 3 trial evaluating cabozantinib in patients with neuroendocrine tumors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
Rhea-AI Summary
Exelixis, Inc. to release Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
earnings
News
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
Rhea-AI Summary
Exelixis and Insilico Medicine enter exclusive license agreement for ISM3091
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none
Stock EXEL logo
Exelixis Inc

Nasdaq:EXEL

EXEL Rankings

#988 Ranked by Market Cap
#860 Ranked by Stock Gains
N/A Ranked by Dividends

EXEL Stock Data

6.92B
255.76M
2.34%
88.14%
2.25%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Alameda

About EXEL

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.